ATS 2019 Virtual Final Program

10:00 Cell Free Hemoglobin as a Mediator of Acute Lung Injury J.A. Bastarache, MD, Nashville, TN 10:25 Nucleic Acid Binding: How RBCs Modulate Immune Responses N.S. Mangalmurti, MD, Philadelphia, PA 10:50 Immunomodulatory Roles of CD71+ Erythroid Cells (Immature Red Blood Cells) in Health and Disease S. Elahi, PhD, Edmonton, Canada CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM CME Credits Available: 2 MOC Points Available: 2 C7 WHAT PULMONOLOGISTS NEED TO KNOW ABOUT CANCER IMMUNOTHERAPY Assemblies on Thoracic Oncology; Allergy, Immunology and Inflammation; Clinical Problems 9:15 a.m. - 11:15 a.m. KBHCCD Ballroom A Two (Level 2) Target Audience Pulmonary providers: practicing and in-training physicians, NP and PA in either private and academic settings who care for patients undergoing cancer immunotherapy or see patients with pulmonary complications of cancer. immunotherapy. Objectives At the conclusion of this session, the participant will be able to: • understand the immunological mechanism of immune checkpoint inhibitor therapy; • recognize and diagnosis pulmonary complications of immune checkpoint inhibitors; • appropriately manage patients with iAE of immune checkpoint inhibitors to balance the risks (decreased anti-tumor immunity) and benefits (need for therapeutic immunosuppression). Cancer immunotherapy and immuno-oncology are rapidly expanding fields in Medicine. Immune checkpoint inhibitors targeting CTLA4 and PD1/PDL1 are now FDA approved for a number of cancers including first and second line therapy of metastatic NSCLC (IV) and Stage III (NSCLC) as well as an increasing number of other malignancies. This represents the fastest expanding therapy in oncology. Pulmonary providers are increasingly involved with many aspects of cancer immunotherapy. This mainly includee assessment of predictive biomarkers such as (PD-L1) and the management of an increasing number of pulmonary complications of these agents which occur in 5 to up the 29% of these patients. Understanding the mechanisms of immune checkpoint inhibitors and the appropriate recognition, diagnosis and management of these potentially life threatening complications are crucial to patient outcomes. This multi-disciplinary session will provide attendees with the skills to do this in their daily practice in a case based fashion. Chairing: M.P. Rivera, MD, ATSF, Chapel Hill, NC C.R. Sears, MD, Indianapolis, IN P. Camus, MD, CHU Le Bocage, Dijon, France 9:15 Immune Checkpoint Inhibitors for Cancer Therapy E.Moon, MD, Philadelphia, PA 9:45 Effectiveness and Immune Related Adverse Events of Immune Checkpoint Inhibitor Therapy in Lung Cancer P. Forde, MBBCh,Baltimore, MD 10:15 Imaging Findings of Immune Checkpoint Inhibitor Related Pneumonitis M. Nishino, MD, Boston, MA 10:35 Diagnosis and Treatment of Immune Checkpoint Inhibitor Related Pneumonitis J.D. Possick, MD, New Haven, CT 10:55 Multidisciplinary Case Discussion T. Peikert, MD, Rochester, MN This session and the International Conference are supported by an educational grant from AstraZeneca LP. All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests. CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM CME Credits Available: 2 C8 BRONCHIECTASIS: MOVING BEYOND THE VICIOUS CYCLE Assembly on Pulmonary Infections and Tuberculosis 9:15 a.m. - 11:15 a.m. KBHCCD Ballroom A Three (Level 2) Target Audience Pulmonologists, Post-graduate trainees, Advanced Practitioners, Respiratory Therapists Objectives At the conclusion of this session, the participant will be able to: • learn about potential biomarkers for disease severity in bronchiectasis; • understand recent development in the study of the lung microbiome; • discuss strategies for future studies in bronchiectasis: phenotyping study populations, drugs in the pipeline. Cole’s vicious cycle of infection, inflammation, and airway damage has traditionally been the accepted model of bronchiectasis pathophysiology. This session will highlight recent research that has uncovered more detailed mechanisms that underlie this simple paradigm. Discovery of genetic variants in the bronchiectasis patient is providing perspective as to how a patient may be vulnerable to the vicious cycle. Biomarkers have been proposed to measure inflammation and infection. Data from research into the bronchiectasis microbiome and mycobiome is challenging the validity of the traditional use and application of sputum cultures. Efforts to better phenotype the heterogeneous bronchiectasis population are underway. Priorities for future drug trials will be discussed. Chairing: P.J. McShane, MD, Chicago, IL K.L. Winthrop, MD, MPH, Portland, OR A.E. O’Donnell, MD, Washington, DC ATS 2019 • Dallas, TX 224 TUESDAY • MAY 21